In an industrial suburb of Shanghai, a changing of the guard in drugmaking is unfolding.
Engineers inspect a line of enormous stainless-steel vats where a biologic drug will soon begin production, derived from cells originating in hamster ovaries. With each vat big enough to make 50,000 litres of the medicine, the facility is just one piece of evidence of a biopharma industry boom under way across China.
The plant belongs to BiBo Pharma, which began construction in February and is already a month ahead of schedule, propelled by rapid-fire approvals and hands-on support from the local Lingang district government.
您已阅读4%（617字），剩余96%（15287字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。